Q3 2024 Hansa Biopharma AB Earnings Call Transcript
Key Points
- Hansa Biopharma AB (STU:24H) achieved its highest ever quarterly IDEFIRIX sales in Q3 2024, marking the fourth consecutive quarter of solid sales performance.
- The company has secured reimbursement in 15 European markets, covering approximately 75% of the European transplant market.
- Significant scientific advancements were made, including the completion of patient randomization in the US phase three trial for kidney transplantation.
- The company is progressing well with its pipeline, including the Good-IdeS-12 Phase 3 trial in anti-GBM disease, which is 86% enrolled.
- Hansa Biopharma AB (STU:24H) has a strong financial position with cash and cash equivalents totaling SEK554 million as of September 30, 2024.
- A provision of SEK29.7 million was recorded in Q3 2024 due to a revised estimate of a one-time retroactive adjustment of cumulative sales since launch in 2020.
- SG&A expenses remain high, totaling SEK76 million in Q3 2024, despite restructuring efforts.
- R&D expenses are significant, totaling SEK79.6 million in Q3 2024, reflecting ongoing clinical trial activities.
- The company faces challenges in pricing negotiations, as evidenced by the need for provisions related to early access programs.
- There is uncertainty regarding the next steps for the AMR program following phase two data, with no immediate plans for a phase three trial.
Good morning and welcome to the Hansa Biopharma interim report for January to September 2024 conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Søren Tulstrup, President and CEO of Hansa BioPharma. Please go ahead.
Thank you, Operator. Good afternoon, good morning and welcome to the Hansa Biopharma conference call to review the Q3 results for 2024. I'm Søren Tulstrup, President and CEO of Hansa Biopharma. Joining me today is Evan Ballantyne, Chief Financial Officer; and Hitto Kaufmann, chief R&D Officer.
Please turn to slide 2. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during this presentation and you should therefore apply appropriate caution. Now please turn to slide 3 and an overview of today's agenda.
Today, we'll discuss the progress we made during the third quarter, 2024 and review our near term priorities. The presentation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
